JP2007506434A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506434A5 JP2007506434A5 JP2006528260A JP2006528260A JP2007506434A5 JP 2007506434 A5 JP2007506434 A5 JP 2007506434A5 JP 2006528260 A JP2006528260 A JP 2006528260A JP 2006528260 A JP2006528260 A JP 2006528260A JP 2007506434 A5 JP2007506434 A5 JP 2007506434A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- seneca valley
- mutant
- sequence
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 96
- 241000700605 Viruses Species 0.000 claims 77
- 241000837158 Senecavirus A Species 0.000 claims 51
- 210000004027 cell Anatomy 0.000 claims 38
- 108091033319 polynucleotide Proteins 0.000 claims 26
- 102000040430 polynucleotide Human genes 0.000 claims 26
- 239000002157 polynucleotide Substances 0.000 claims 26
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 210000004881 tumor cell Anatomy 0.000 claims 24
- 238000012360 testing method Methods 0.000 claims 17
- 239000002773 nucleotide Substances 0.000 claims 16
- 125000003729 nucleotide group Chemical group 0.000 claims 16
- 230000003612 virological effect Effects 0.000 claims 16
- 241000710190 Cardiovirus Species 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 210000000234 capsid Anatomy 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 11
- 241000709664 Picornaviridae Species 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 244000309459 oncolytic virus Species 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 241000710188 Encephalomyocarditis virus Species 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 239000002299 complementary DNA Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 4
- 239000003053 toxin Substances 0.000 claims 4
- 231100000765 toxin Toxicity 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 241000725110 Vilyuisk human encephalomyelitis virus Species 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 201000002491 encephalomyelitis Diseases 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000000415 inactivating effect Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002458 infectious effect Effects 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 238000002703 mutagenesis Methods 0.000 claims 3
- 231100000350 mutagenesis Toxicity 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 108090000565 Capsid Proteins Proteins 0.000 claims 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 238000002835 absorbance Methods 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 claims 2
- 239000013592 cell lysate Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 101710151906 31 kDa protein Proteins 0.000 claims 1
- 101001050984 Apple stem grooving virus (strain Korea) Putative movement protein Proteins 0.000 claims 1
- 101001050983 Apple stem grooving virus (strain P-209) Probable movement protein Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010057248 Cell death Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 241000907335 Sal Vieja virus Species 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000020654 modulation by virus of host translation Effects 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50618203P | 2003-09-26 | 2003-09-26 | |
| PCT/US2004/031504 WO2005030139A2 (en) | 2003-09-26 | 2004-09-23 | Seneca valley virus based compositions and methods for treating disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007506434A JP2007506434A (ja) | 2007-03-22 |
| JP2007506434A5 true JP2007506434A5 (enExample) | 2007-10-18 |
Family
ID=34393123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528260A Pending JP2007506434A (ja) | 2003-09-26 | 2004-09-23 | ＳｅｎｅｃａＶａｌｌｅｙウイルスベースの組成物および疾患の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1668025B1 (enExample) |
| JP (1) | JP2007506434A (enExample) |
| KR (1) | KR20060103890A (enExample) |
| CN (1) | CN1875028B (enExample) |
| AU (1) | AU2004275832A1 (enExample) |
| BR (1) | BRPI0414810A (enExample) |
| CA (1) | CA2540177A1 (enExample) |
| DK (1) | DK1668025T3 (enExample) |
| IL (1) | IL174430A0 (enExample) |
| MX (1) | MXPA06003318A (enExample) |
| SG (1) | SG149069A1 (enExample) |
| WO (1) | WO2005030139A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US7638318B2 (en) | 2003-09-26 | 2009-12-29 | Norvartis Ag | Seneca Valley virus based compositions and methods for treating disease |
| WO2007047256A2 (en) * | 2005-10-13 | 2007-04-26 | Neotropix, Inc. | Svv-based animal vaccines and uses thereof |
| CA3045771A1 (en) | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
| CN105925728B (zh) * | 2016-06-01 | 2019-09-20 | 华南农业大学 | 一种塞内加谷病毒实时荧光定量pcr检测引物及试剂盒 |
| US10323069B2 (en) * | 2016-08-23 | 2019-06-18 | Regents Of The University Of Minnesota | Senecavirus A antigens and methods of use |
| EP3652325A4 (en) * | 2017-07-14 | 2021-09-15 | Oncorus, Inc. | ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE |
| CN107253978B (zh) * | 2017-08-13 | 2020-11-20 | 中牧实业股份有限公司 | 塞尼卡谷病毒结构蛋白抗体酶联免疫检测试剂盒 |
| CN107513524B (zh) * | 2017-09-30 | 2021-02-09 | 中牧实业股份有限公司 | 一株猪塞内加谷病毒毒株及其应用 |
| CN108467904B (zh) * | 2018-05-24 | 2021-11-19 | 华南农业大学 | 检测塞尼卡谷病毒的rt-lamp引物组、试剂盒及应用 |
| CN109182278B (zh) * | 2018-10-12 | 2021-08-06 | 河南省动物疫病预防控制中心 | 塞尼卡谷病毒毒株及其应用 |
| SG11202104887UA (en) * | 2018-11-13 | 2021-06-29 | Oncorus Inc | Encapsulated polynucleotides and methods of use |
| CN109234464A (zh) * | 2018-11-23 | 2019-01-18 | 山东新希望六和集团有限公司 | 用于检测塞尼卡谷病毒的引物及探针、荧光定量pcr试剂盒及方法和应用 |
| CN111733144A (zh) * | 2019-03-25 | 2020-10-02 | 金宇保灵生物药品有限公司 | 一种塞内卡病毒的纯化方法及病毒液的浓缩纯化方法 |
| CN112433049B (zh) * | 2019-06-24 | 2023-08-18 | 中国动物疫病预防控制中心(农业农村部屠宰技术中心) | 检测塞内卡病毒抗体的试剂及其应用 |
| BR112022000928A2 (pt) | 2019-07-19 | 2022-03-08 | Seneca Therapeutics Inc | Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma |
| CN110923211A (zh) * | 2019-12-25 | 2020-03-27 | 哈药集团生物疫苗有限公司 | 塞内卡病毒分离株、塞内卡病毒病灭活疫苗及其制备方法 |
| CN111286491A (zh) * | 2020-02-03 | 2020-06-16 | 河南省动物疫病预防控制中心 | 猪塞内卡病毒核酸标准物及其应用 |
| CN111849925B (zh) * | 2020-07-06 | 2022-06-03 | 马忠仁 | 一种抗结肠癌疫苗及其制法 |
| CN111798712B (zh) * | 2020-07-15 | 2021-10-29 | 周晓庆 | 噬菌体侵染细菌3d智能模拟方法 |
| CN111944764A (zh) * | 2020-08-31 | 2020-11-17 | 信阳农林学院 | 一种表达猪塞内加谷病毒蛋白的细胞系、构建方法和应用 |
| CN112390861A (zh) * | 2020-09-30 | 2021-02-23 | 信阳农林学院 | 表达猪塞内加谷病毒vp1蛋白的细胞系、构建方法和应用 |
| CN117281824B (zh) * | 2023-08-11 | 2025-10-21 | 华南农业大学 | Trim基因的过表达剂在制备抑制猪塞内卡病毒复制的产品中的应用 |
| CN117487006B (zh) * | 2023-12-29 | 2024-04-12 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种抗a型塞内卡病毒的单克隆抗体以及抗原表位及应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
-
2004
- 2004-09-23 EP EP04789044.7A patent/EP1668025B1/en not_active Expired - Lifetime
- 2004-09-23 CN CN200480030443XA patent/CN1875028B/zh not_active Expired - Lifetime
- 2004-09-23 AU AU2004275832A patent/AU2004275832A1/en not_active Abandoned
- 2004-09-23 BR BRPI0414810-0A patent/BRPI0414810A/pt not_active IP Right Cessation
- 2004-09-23 JP JP2006528260A patent/JP2007506434A/ja active Pending
- 2004-09-23 SG SG200809634-9A patent/SG149069A1/en unknown
- 2004-09-23 WO PCT/US2004/031504 patent/WO2005030139A2/en not_active Ceased
- 2004-09-23 DK DK04789044.7T patent/DK1668025T3/da active
- 2004-09-23 KR KR1020067008081A patent/KR20060103890A/ko not_active Withdrawn
- 2004-09-23 CA CA002540177A patent/CA2540177A1/en not_active Abandoned
- 2004-09-23 MX MXPA06003318A patent/MXPA06003318A/es unknown
-
2006
- 2006-03-21 IL IL174430A patent/IL174430A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007506434A5 (enExample) | ||
| Bello et al. | Diagnostic and vaccination approaches for Newcastle disease virus in poultry: The current and emerging perspectives | |
| Huang et al. | Targeting AAV vectors to the central nervous system by engineering capsid–receptor interactions that enable crossing of the blood–brain barrier | |
| Combelas et al. | Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence | |
| Chang et al. | Merkel cell carcinoma: a virus-induced human cancer | |
| Dobrikova et al. | Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype | |
| Wilton et al. | Effect of formaldehyde inactivation on poliovirus | |
| Gromeier et al. | Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence | |
| DeJesus et al. | Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence | |
| CN1875028B (zh) | 基于 Seneca Valley 病毒的组合物以及疾病的治疗方法 | |
| JP2008533988A5 (enExample) | ||
| Brown et al. | Cell-dependent role for the poliovirus 3′ noncoding region in positive-strand RNA synthesis | |
| JP2008533988A (ja) | セネカバレーウイルスを基盤とする組成物及び疾患を治療する方法 | |
| Wetzel et al. | Efficiency of viral entry determines the capacity of murine erythroleukemia cells to support persistent infections by mammalian reoviruses | |
| Zade et al. | Biased selection of propagation-related TUPs from phage display peptide libraries | |
| Kajigaya et al. | Isolation and characterization of defective-interfering particles of poliovirus Sabin 1 strain | |
| JP6618360B2 (ja) | 薬物送達タンパク質の輸送向上変異体の単離 | |
| Leser et al. | VP1 is the primary determinant of neuropathogenesis in a mouse model of enterovirus D68 acute flaccid myelitis | |
| Liu et al. | A specific host cellular protein binding element near the 3′ end of mouse hepatitis virus genomic RNA | |
| Liu et al. | Identification and Genome Characterization of a Novel Muscovy Duck‐Origin Goose Parvovirus with Three Recombinant Regions between Muscovy Duck Parvovirus and Goose Parvovirus | |
| Yeo et al. | Genetic modification regulates pathogenicity of a fowl adenovirus 4 strain after cell line adaptation (genetic mutation in FAdV-4 lowered pathogenicity) | |
| Brochu-Lafontaine et al. | Addition of exogenous polypeptides on the mammalian reovirus outer capsid using reverse genetics | |
| US20100278863A1 (en) | Reoviruses | |
| Bradrick et al. | A predicted secondary structural domain within the internal ribosome entry site of echovirus 12 mediates a cell-type-specific block to viral replication | |
| TWI686474B (zh) | 強毒性腸病毒71之穩定生產及其利用 |